Search | Clinical Trials Finder

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: diffusion-weighted magnetic resonance imaging, 4-dimensional computed tomography, fludeoxyglucose F 18, FDG-PET; Device · Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Allergic Asthma
Interventions: Whole lung antigen challenge, segmental allergen challenge; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Vismodegib; Biological · Procedure · Drug
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Migraine, Atrial Fibrillation
Interventions: Radiofrequency catheter ablation; Procedure
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more

Conditions: Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: computed tomography, positron emission tomography, 11C topotecan, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography; Radiation · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Muscular Dystrophy, Duchenne
Interventions: Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram; Other
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 15 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lung Cancer
Interventions: PET/CT Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy; Radiation · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions: 129Xe Hyperpolarized; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Respiratory Control in Premature Infants
Interventions: Bedside Physiology study, Carotid Body Function Test, Room Air Challenge, Hypoxia Challenge Test, Effects of Nasal Cannula Flow, Magnetic Resonance Imaging, Echocardiogram, Blood Sample; Other · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 28 Days
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Hypertension, Congenital Heart Disease, Pediatric Congenital Heart Disease
Interventions: cardiac catheterization, Cardiac MRI; Procedure · Radiation
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 25 Years
Enrollment: 35 participants
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Cystic Fibrosis
Interventions: 129Xe; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 8 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia

Conditions: Lung Cancer (NSCLC), Radiation
Interventions: MRI; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Diseases
Interventions: perfluorinated gas/oxygen mixture; Drug
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Interstitial Lung Diseases
Interventions: Hyperpolarized 129Xe; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis in Children
Interventions: 19F MRI; Combination Product
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis
Interventions: hyperpolarized Xenon gas; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 21 Years
Enrollment: 20 participants
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Conditions: Non Small Cell Lung Cancer
Interventions: CMP-001, Atezolizumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 129Xe Hyperpolarized; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

AsthMatic Inflammation and Neurocircuitry Activation (MINA)

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

11C Topotecan PET Imaging

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy

Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating

Developing New Ways to Detect Respiratory Impairment Early in ALS

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Prematurity-Related Ventilatory Control

Image-based Multi-scale Modeling Framework of the Cardiopulmonary System: Longitudinal Calibration and Assessment of Therapies in Pediatric Pulmonary Hypertension

BEGIN Novel ImagiNG Biomarkers

GCC 2546- Motion Management

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

129 Xenon Imaging in Patients Treated With Sotatercept